Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis

Loading news article.

Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis | WAPE

Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis

Article summary

Related companies

Comments —